429 results on '"Gramegna, Andrea"'
Search Results
2. Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease
3. Covid-19 in cystic fibrosis patients compared to the general population: Severity and virus-host cell interactions
4. Maternal and fetal outcomes in multiparous women with Cystic Fibrosis
5. Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
6. Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis
7. Walking the path of treatable traits in interstitial lung diseases
8. Severity of SARS-CoV-2 infection in a hospital population: a clinical comparison across age groups
9. Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
10. Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?
11. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
12. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
13. Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis
14. Standards for the care of people with cystic fibrosis; establishing and maintaining health
15. The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus
16. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
17. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis
18. The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic
19. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
20. Antibiotics for lung disease and cancer
21. Standards of care and educational gaps in adult cystic fibrosis units: an ERS survey
22. A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
23. Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients
24. Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study
25. Prevalence and serotyping of S. pneumoniae in a large vaccine-naive cohort of adults with cystic fibrosis
26. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
27. Diagnostic delay in bronchiectasis: an Italian perspective
28. Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review
29. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor–tezacaftor–ivacaftor combination: a 1-year observational study
30. Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation
31. Post-COVID-19 sequelae
32. Respiratory failure in COVID-19: a patient's perspective and clinical cases
33. Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.
34. Standards of care and educational gaps in adult cystic fibrosis units: a European Respiratory Society survey.
35. Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.
36. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
37. Standards for the care of people with cystic fibrosis; establishing and maintaining health
38. Idiopathic interstitial pneumonia in a patient with Von Hippel-Lindau syndrome: a first case
39. Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis
40. Standards for the care of people with cystic fibrosis (CF)
41. How to Identify Causes and Predisposing Factors in Bronchiectasis
42. An international perspective on hospitalized patients with viral community-acquired pneumonia
43. Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
44. Bronchiectasis and cardiovascular risk: a systematic review and meta-analysis
45. The Successful Procedures Of weaning from Tracheostomy (SPOT) study: preliminary analysis of predictive factors for failure and validation of the QsQ score
46. Bronchiectasis associated to connective tissue diseases: a single-center experience
47. Single cells RNA sequencing of peripheral blood mononuclear cells reveals that hyperinflammatory monocytes are associated with the risk of Mycobaterium abscessus pulmonary disease
48. Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
49. COVID-19 multidisciplinary high dependency unit: the Milan model
50. Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.